Karyopharm Therapeutics Inc. (KPTI) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
KPTI currently has 22.7M outstanding shares. with significant dilution risk as 33.2M authorized shares could dilute existing holders by 146.4%. The company has significantly diluted shareholders by 196704.91% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 22.7M shares outstanding |
23M | 33M |
| May 04, 2026 |
S-3 filing: This prospectus relates to the resale from time to time of up to 8,843,036 shares of common stock of Karyopharm Therapeutics Inc. by the selling stockholder listed on page 11, including their donees, pledgees, assignees, transferees or other successors-in-interest, which consist of 1,030,354 outstanding shares of our common stock held by the selling stockholder, 3,391,164 shares of our common stock issuable upon the exercise of outstanding pre-funded warrants held by the selling stockholder and 4,421,518 shares of our common stock issuable upon the exercise of outstanding warrants to purchase shares of our common stock held by the selling stockholder. |
8.7M | 35M |
| May 04, 2026 |
S-3 filing: The company may offer and sell securities from time to time in one or more offerings of up to $400,000,000 in aggregate offering price. |
18M | 38M |
| Nov 03, 2025 |
10-Q filing | 17050.9M shares outstanding |
17B | 0 |
| Nov 03, 2025 |
S-3 filing: This prospectus relates to the resale from time to time of up to 9,569,707 shares of common stock of Karyopharm Therapeutics Inc. by the selling stockholders listed on page 13. |
8.7M | 26M |
| Aug 11, 2025 |
10-Q filing | 8.7M shares outstanding |
8.7M | 4.3M |
| May 12, 2025 |
10-Q filing | 8.6M shares outstanding |
8.6M | 4.3M |
| Feb 25, 2025 |
Stock Split
8-K filing: Stock split 1-for-15 | Outstanding: 126,240,054 → 8,416,003 |
8.4M | 4.6M |
| Feb 19, 2025 |
10-K filing | 126.2M shares outstanding |
130M | 68M |
| Nov 05, 2024 |
10-Q filing | 125.3M shares outstanding |
130M | 69M |
| Aug 06, 2024 |
10-Q filing | 121.0M shares outstanding |
120M | 74M |
| May 30, 2024 |
S-3 filing: This S-3 filing relates to the resale of up to 45,776,213 shares of common stock issuable upon the exercise of warrants previously issued to selling stockholders in privately negotiated convertible notes exchanges. |
120M | 79M |
| May 08, 2024 |
8-K filing: Karyopharm Therapeutics Inc. entered into agreements to exchange $148.0 million of existing convertible notes for $111.0 million of new secured convertible notes and warrants to purchase up to 46.0 million shares of common stock, along with other financing transactions. |
110M | 35M |
| May 08, 2024 |
10-Q filing | 115.5M shares outstanding |
120M | 33M |
| Feb 29, 2024 |
10-K filing | 114.2M shares outstanding |
110M | 35M |
| Nov 02, 2023 |
10-Q filing | 114.4M shares outstanding |
110M | 34M |
| Aug 02, 2023 |
10-Q filing | 114.2M shares outstanding |
110M | 35M |
| May 04, 2023 |
10-Q filing | 113.5M shares outstanding |
110M | 35M |
| Feb 17, 2023 |
10-K filing | 113.3M shares outstanding |
110M | 36M |
| Feb 17, 2023 |
S-3 filing: The company is filing an S-3 to register the offering and sale of up to $300,000,000 of debt securities, common stock and preferred stock. Additionally, the company may offer and sell shares of common stock up to $100,000,000 from time to time through Jefferies LLC, acting as its sales agent. |
80M | 69M |
| Dec 23, 2022 |
S-3 filing: This S-3 filing registers 41,329,471 shares of common stock for resale by selling stockholders, including 31,791,908 outstanding shares and 9,537,563 shares issuable upon the exercise of outstanding warrants. |
80M | 41M |
| Nov 03, 2022 |
10-Q filing | 80.2M shares outstanding |
80M | 0 |
| Aug 04, 2022 |
10-Q filing | 79.7M shares outstanding |
80M | 0 |
| May 05, 2022 |
10-Q filing | 79.4M shares outstanding |
79M | 0 |
| Mar 01, 2022 |
10-K filing | 79.2M shares outstanding |
79M | 0 |
| Nov 03, 2021 |
10-Q filing | 75.5M shares outstanding |
76M | 0 |
| Aug 05, 2021 |
10-Q filing | 75.5M shares outstanding |
75M | 0 |
| May 04, 2021 |
10-Q filing | 75.1M shares outstanding |
75M | 0 |
| Feb 24, 2021 |
10-K filing | 74.6M shares outstanding |
75M | 0 |
| Nov 02, 2020 |
10-Q filing | 73.6M shares outstanding |
74M | 0 |
| Aug 04, 2020 |
10-Q filing | 73.5M shares outstanding |
73M | 0 |
| May 05, 2020 |
10-Q filing | 73.1M shares outstanding |
73M | 0 |
| Feb 26, 2020 |
10-K filing | 65.5M shares outstanding |
66M | 0 |